Eli Lilly’s profit beats on demand for newer drugs

(Reuters) – Eli Lilly and Co reported a bigger-than-expected quarterly adjusted profit as the drugmaker benefited from higher demand for its newer products including diabetes treatment Trulicity and psoriasis drug Taltz.

Leave a Reply

Your email address will not be published. Required fields are marked *